Document ID: chunk:federal_register_of_legislation:F2024C01086:clause:1_964:p1
Version: federal_register_of_legislation:F2024C01086
Segment Type: clause
Provision Reference: sch 1 cl 964 (pt 1/2)
Character Range: 356448–359740

964                                                                                                          Attendance by a consultant physician in the practice of the consultant physician's specialty of psychiatry or paediatrics, as a member of a multidisciplinary case conference team, to participate in a mental health case conference of at least 45 minutes, with the multidisciplinary case conference team                                                                                                                                                                                                   243.20

Division 2.17—Group A17 and Subgroup 7 of Group A7: Domiciliary and residential medication management reviews

            Note: Items in Subgroup 7 of Group A7 are set out in Division 2.10.

2.17.1  Meaning of living in a community setting
  In items 900 and 245:
living in a community setting: a patient is living in a community setting if the patient is not an in‑patient of a hospital or a care recipient in a residential aged care facility.

2.17.2  Meaning of residential medication management review
 (1) In items 903 and 249:
residential medication management review means a collaborative service provided by a general practitioner (for item 903), or a prescribed medical practitioner (for item 249), and a pharmacist to review the medication management needs of a care recipient in a residential aged care facility.
 (2) A medical practitioner's involvement in a residential medication management review includes all of the following:
 (a) discussing the proposed review with the resident and seeking the resident's consent to the review;
 (b) collaborating with the reviewing pharmacist about the pharmacist's involvement in the review;
 (c) providing input from the resident's most recent comprehensive medical assessment or, if such an assessment has not been undertaken, providing relevant clinical information for the review and for the resident's records;
 (d) subject to subclause (4), participating in a post‑review discussion (either face‑to‑face or by telephone) with the pharmacist to discuss the outcomes of the review including:
 (i) the findings of the review; and
 (ii) medication management strategies; and
 (iii) means to ensure that the strategies are implemented and reviewed, including any issues for implementation and follow‑up;
 (e) developing or revising the resident's medication management plan after discussion with the reviewing pharmacist, and finalising the plan after discussion with the resident.
 (3) A medical practitioner's involvement in a residential medication management review also includes:
 (a) offering a copy of the medication management plan to the resident (or the resident's carer or representative if appropriate); and
 (b) providing copies of the plan for the resident's records and for the nursing staff of the residential aged care facility; and
 (c) discussing the plan with nursing staff if necessary.
 (4) A post‑review discussion is not required if:
 (a) there are no recommended changes to the resident's medication management arising out of the review; or
 (b) any changes are minor in nature and do not require immediate discussion; or
 (c) the pharmacist and medical practitioner agree that issues arising out